Posaconazole 200 mg (liquid) by mouth 3 times per day.

Posaconazole

Sex: Female, Male

Region of Enrollment

Participant Diagnosis

Participant's first induction chemotherapy, either with a clofarabine-based regimen or a cytarabine-based regimen. Exception listed as miscellaneous chemotherapy treatment, and include AZD1152 (an experimental aurora kinase inhibitor) alone (1 participant) or in combination with low-dose cytarabine (2 participants).

Chemotherapy Received

Pharmacokinetic samples were obtained on day 1, day 3 and day 10 of prophylaxis. A total of 15 samples (3 ml each sample) per participant were obtained, with thrice daily dosing planned around standard meal times. On day 1 and day 3 of prophylaxis sampling was done pre dose (0), and at 3, 5, 10 and 24 hours (±10 minutes) post dose from the time of the first dose of the day. On day 10 of prophylaxis sampling was done pre dose (0), and at 3, 5, and 10 hours (±10 minutes) post dose from the time of the first dose of the day.
Posaconazole levels were assayed by high performance liquid chromatography (HPLC). The testing range for posaconazole is from 125 - 5000 ng/ml. There are no established therapeutic ranges for posaconazole.

Posaconazole (Females)

Posaconazole (Males)

Maximum Observed Concentration in Plasma (Cmax)

Overall Study

Jorge Cortes, MD/Professor, Leukemia Department

Leukemia

Fungal Infection

200 mg (liquid) by mouth 3 times per day.

UT MD Anderson Cancer Center

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

Phase II Study of the Pharmacokinetics of Posaconazole Prophylaxis in Relapsed or Refractory Patients With Acute Leukemia

M.D. Anderson Cancer Center

Schering-Plough

myelodysplastic syndromes

carbohydrate

myelodysplastic syndromes/carbohydrate

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

Najkompletnejšia databáza liečivých bylín podporovaná vedou